08:14 AM EDT, 06/09/2025 (MT Newswires) -- NewAmsterdam Pharma ( NAMS ) said Monday that obicetrapib significantly reduced plasma biomarkers associated with Alzheimer's disease in a phase 3 trial.

The study showed statistically significant improvements in p-tau217 levels in both the full patient population and among ApoE4 carriers, the company said.

These results support a potential role for CETP inhibitors in slowing Alzheimer's-related symptoms, NewAmsterdam said.

The AD sub-study included over 1,700 patients and evaluated multiple biomarkers over 12 months, the company said, all showing favorable changes with obicetrapib.

NewAmsterdam said obicetrapib was well-tolerated across trials and continues to be studied in an ongoing phase 3 trial.

NewAmsterdam shares were more than 9% higher in premarket trading.